ARS Pharma Submits SNDA For Neffy 1 Mg Dose For Pediatric Type I Allergic Reactions
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – ARS Pharmaceuticals Inc. (SPRY) announced the submission of a supplemental New Drug Application (sNDA) for neffy 1 mg for the treatment of Type I Allergic Reactions, including anaphylaxis, in children who weigh 15 to 30 kg. Pharmacokinetic (PK) data for neffy 1mg were
:max_bytes(150000):strip_icc():format(jpeg)/PropertyValuation-4ecdfe3a87144fe998087ef433f49c13.jpeg "Is There a Gender Gap in Home Equity Loans?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1346781100-2724c28da6b2479b88db9d1337ebe926.jpg "Buy Now, Pay Later or Rent-to-Own: Which Is the Smarter Way to Pay for Purchases?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1917868586-d64880817bca4098bc8be36bbd17a4e9.jpg "Should You Trade Options on Spot Bitcoin ETFs?")